Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature Authors: Maxime Quaggetto, Thouraya Ben Salem, Julien Haroche, Julien Campagne, Quentin Moyon, Raphael Lhote, Zahir Amoura, Fleur Cohen Aubart Published: 2025 ABSTRACT Background and aim:Sarcoidosis is an inflammatory granulomatous disease of unknown cause affecting the lungs and frequently extra-thoracic organs. Several immunosuppressive agents have been evaluated in patients refractory to steroids or as steroids-sparing treatments with low level of evidence and conflicting results. JAK inhibitors (JAKi) are novel immunosuppressive agents and recent reports suggested their potential to induce disease response. We report four new sarcoidosis cases treated with JAKi and present a systematic review of the literature.Methods:We describe four new cases and conducted a literature review using Pubmed, Medline, Embase and Cochrane Library. All English-language reports of sarcoidosis patients treated with JAKi published between January 2004 and 2024 were included.Results:We included 4 cases, as well as 45 cases from a systematic review of the literature, reported in 21 articles, leading to a cohort of 49 patients (female 53%, median [IQR 25-75] age 55 [43-60] years). Most cases had pulmonary and cutaneous sarcoidosis, while cardiac and neurological sarcoidosis were less frequent. Indication for JAKi were: steroid sparing agent (29%), refractory disease (22%), non-sarcoidosis indication (10%) and not specified (39%). Most patients received Tofacitinib 5 mg twice daily. Median corticosteroids dosage at treatment initiation was 15 [10-25] mg/day. After a median follow-up of 8 [6-12] months, complete response was achieved in 45% of cases and partial response in 49%, with few adverse events reported. Corticosteroids were discontinued in 11/23 (48%) and reduced in 6/23 (26%).Conclusions:JAK inhibitors appear to be a promising therapeutic option in sarcoidosis patients who are corticosteroid-dependent or refractory to conventional immunosuppressants. Prospective studies are now needed to confirm their efficacy and long-term safety. Table S1.Previous Treatments Received Before JAKi in the 49 Reported Sarcoidosis CasesVariablesn=49Oral corticosteroids39/49 (80)Methotrexate33/49 (67)Hydroxychloroquine18/49 (36)Infliximab13/49 (27)Topical corticosteroids11/49 (22)Mycophenolate mofetil7/49 (14)Adalimumab7/49 (14)Azathioprine7/49 (14)Minocycline/Doxycycline4/49 (8)Topical CNI3/49 (6)Leflunomide3/49 (6)Rituximab3/49 (6)Cyclophosphamide2/49 (4)Intravenous immunoglobulin2/49 (4)Tocilizumab2/49 (4)Apremilast2/49 (4)Tacrolimus1/49 (2)Ciclosporin1/49 (2)Thalidomide1/49 (2)Anakinra1/49 (2)Anti-tuberculosis therapy1/49 (2)Dapsone1/49 (2)Tildrakizumab1/49 (2)Abbreviations: CNI, calcineurin inhibitor; JAKi, Janus kinase inhibitor.Categorical variables are expressed as No. (%). Previous Treatments Received Before JAKi in the 49 Reported Sarcoidosis Cases Abbreviations: CNI, calcineurin inhibitor; JAKi, Janus kinase inhibitor. Categorical variables are expressed as No. (%). Table S2.Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 45 Sarcoidosis Cases Treated With JAKi Published to DateRefGenderAgeOrgan involvedDisease durationFollow-up on JAKiTreatmentPrevious treatmentsOutcome(23)F59S, ENT, L18 y12 mRUXO 5mgx2/dGC, MTX, HCQ, AZA, LEF, INF, ADAPartial response: S & L M3, GC tapered at 8 mg/d(34)M77LN, L, KUnknown14 mTOFA 10mgx2/dGC, IgIV, CsA, RTXComplete response: LN, L & K(34)F43LN, CS, CNS, JUnknown12 mTOFA 5-10mgx2/dGC, HCQ, MTXPartial response: LN, CS, CNS, J, GC tapered at 5 mg/d(34)M42LN, M, KUnknown7 mTOFA 5-10mgx2/dGC, HCQComplete response: LN, M & K(34)M20LN, G, KUnknown8 mTOFA 10mgx2/dIFNComplete response: LN, G, K(34)M74LN, L, K, Ca2+Unknown10 mTOFA 5-10mgx2/dNonePartial response: K, Ca2+ M10(34)M67LN, L, KUnknown4 mTOFA 10mgx2/dGCPartial response: Ca2+, L, K M3, GC tapered at 10 mg/d(34)F36E, KUnknown8 mTOFA 5mgx2/dGC, MTX, MMF, IFNPartial response: E, K, GC maintained at 5 mg/d(19)F63S, CS, L6 y6 mTOFA 5mgx2/dGC, MTX, IFNComplete response: S M3, CS M6(19)F55S, E, ENT6 y6 mTOFA 5mgx2/dGC, MTX, HCQPartial response: S, E, ENT, GC withdrawn(19)M50-59S, Spl, ENT, L5 y12 mTOFA 5-10mgx2/dGC, MTX, HCQComplete response: S M8(19)M50-59S, ENT, L16 y6 mTOFA 5mgx2/dGC, MTXPartial response: S M6, GC withdrawn(19)M57S, E, ENT, L22 y6 mTOFA 5mgx2/dGC, MTXPartial response: S M6, GC withdrawn(19)F50-59S, ENT, L27 y6 mTOFA 5mgx2/dGC, MTXPartial response: S, ENT, L M6, GC tapered at 8 mg/d(19)M56S, L12 y6 mTOFA 5mgx2/dGC, MTX, IFNComplete response: S & L M6(19)M55S, L6 y6 mTOFA 5mgx2/dMTX, AZAPartial response: Stable L M6, GC tapered(19)F50-59S1 y6 mTOFA 5mgx2/dGC, MTXComplete response: S(19)M50-59S, L31 y6 mTOFA 5mgx2/dGC, MTXComplete response: S(32)F48S, L8 y38 mTOFA 5mgx2/dMTX, HCQ, ADA, MIN, TACRO, APRComplete response: S M10, stable L(35)M34S, L, Li, Spl6 y5 mTOFA 5mgx2/dGC, HCQ, ADA+MTXPartial response: S M5, stable L(35)F68S, E25 y7 mTOFA 5mgx2/dTopical GC, Topical CNI, HCQ, MINComplete response: S, E M6(24)F61S, L3 m3 mTOFA 5mgx2/dNoneComplete response: S, L M3(25)F56LN, L, Li, Spl, B, G, Ca2+5 y18 mRUXO 10-15mgx2/dGC, MTX, HCQ, AZA, INF, ADA, DOX, AT, MMF, CP, ANAComplete response: LN, Li, Spl, B, G, Ca2GC tapered(26)F60LN, S, L8 y9 mRUXO 10mgx2/dIntralesional steroid injectionsComplete response: S M5Partial response: L & LN M7(27)F62LN, E, ADA therapy induced disease1 y8 mTOFA 5mgx2/dADA discontinuation, GC, MTXComplete response: E & LN M8Complete response of RA(28)F35LN, J0,2 y3 mBARI 4mgx2/dGCComplete response: J & LN M3(33)M37L4 y16 mTOFA 5mgx2/dGC, MTXL stable disease M16, GC withdrawn(33)M35L2 y1 mTOFA 5mgx2/dGCLost of follow-up(33)F43L9 m16 mTOFA 5mgx2/dGCPartial response: L M12, GC withdrawn(33)M39S, J, L5 y12 mTOFA 5mgx2/dGCPartial response: L M12, GC withdrawn(33)M50S, J, Spl, Ca2+, CNS, L2 y1 mTOFA 5mgx2/dMTX, MMFStable L Worsening of presumed peripheral sarcoid neuropathy(29)F47S, LUnknown9 mTOFA 8mgx2/dTopical GC, GC, PIM, ILKA, DAPPartial response: S, stable L at M9(29)F53S, LUnknown8 mTOFA 8mgx2/dGC, ILKA, TILDComplete response: S M8(29)F75SUnknown4 mTOFA 2.5mgx1/dTopical GC, GC, MTX, ILKAComplete response: S M4(29)F49S, LUnknown7 mTOFA 2.5mgx1/dGC, MTX, Topical CNI, ILKA, HCQPartial response: S(29)F63SUnknown4 mTOFA 4mgx2/dGC, HCQ, MMF, Topical TACROPartial response: S, GC withdrawn(30)F65S11 y6 mTOFA 5mgx1-2/dHCQComplete response: S M6TOFA tapered at 5 mg/d(31)F60LN, S, B, L21 y9 mTOFA 5-10mgx2/dGC, MTX, MMF, IFN, RTX, IVIGComplete response: S, L, LN & B M4(39)M59S, L24 y12 mBARI 4mgx2/dTopical GC, MTXComplete response: S, L M12(41)F59S, L0 y12 mTOFA 5mgx2/dGC, HCQComplete response: S, L M11(38)M44CS, E, L, Li7 y11 mTOFA 7.5mgx2/dGC, MTX, AZA, LEF, INFComplete response: CS, E, Li M11 and L on CT(37)M56S, J30 y18 mUPA 15mgx1/dTopical GC, GC, MTX, ADA, INFComplete response: S, J M18(40)M41S, E1 y6 mABRO 100mgx1/JGCPartial response: S, E M6, GC withdrawn(36)F57S, J, ENT, L19 y24 mTOFA 5mgx2/dGC, MTX, AZA, HCQ, INF, MMF, RTX, THALComplete response :S, J, ENT M24Partial L response, GC tapered 5 mg(42)F53S, Spl, Li, L8 y30 mTOFA 5mgx2/dGC, MTX, AZA, HCQ, ADA, INFInitial Complete response M21Relapse M30, Treatment with SirolimusAbbreviations: ADA, adalimumab; APR, apremilast; AT therapy, anti-tuberculosis therapy; AZA, azathioprine; B, bones; BARI, baricitinib; CNI, calcineurin inhibitor; CNS, central nervous system, CS, cardiac sarcoidosis; d, day; DAP, dapsone; DOX, doxycycline; E, eyes; CP, cyclophosphamide; CICLO, ciclosporine; ENT, ear nose throat; G, gastrointestinal, GC, glucocorticoids; HCQ, hydroxychloroquine; INF, infliximab; IVIG, intravenous immunoglobulin; J, joints; JAKi, Janus kinase inhibitor; L, lung LEF, leflunomide; Li, liver; LN, lymph node; m, month; M, muscle; MIN, minocycline; MMF, mycophenolate mofetil; MTX, methotrexate; P, parotids; PFT, pulmonary function test; PIM, pimecrolimus, RA, rheumatoid arthritis; Ref, reference; RTX, rituximab; RUXO, ruxolitinib; S, skin; Spl, spleen; TACRO, tacrolimus; THAL, thalidomide; TILD, tildrakizumab; TOCI, Tocilizumab; TOFA tofacitinib; y, year Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 45 Sarcoidosis Cases Treated With JAKi Published to Date Abbreviations: ADA, adalimumab; APR, apremilast; AT therapy, anti-tuberculosis therapy; AZA, azathioprine; B, bones; BARI, baricitinib; CNI, calcineurin inhibitor; CNS, central nervous system, CS, cardiac sarcoidosis; d, day; DAP, dapsone; DOX, doxycycline; E, eyes; CP, cyclophosphamide; CICLO, ciclosporine; ENT, ear nose throat; G, gastrointestinal, GC, glucocorticoids; HCQ, hydroxychloroquine; INF, infliximab; IVIG, intravenous immunoglobulin; J, joints; JAKi, Janus kinase inhibitor; L, lung LEF, leflunomide; Li, liver; LN, lymph node; m, month; M, muscle; MIN, minocycline; MMF, mycophenolate mofetil; MTX, methotrexate; P, parotids; PFT, pulmonary function test; PIM, pimecrolimus, RA, rheumatoid arthritis; Ref, reference; RTX, rituximab; RUXO, ruxolitinib; S, skin; Spl, spleen; TACRO, tacrolimus; THAL, thalidomide; TILD, tildrakizumab; TOCI, Tocilizumab; TOFA tofacitinib; y, year Table S3.Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 4 Blau Syndrome Cases Treated with JAKi Published to DateRefGenderAgeOrgan involvedDisease durationJAKi follow-upTreatmentPrevious treatmentsOutcome(82)F25S, E, J2.5 y21 mTOFA 5mgx2/d then BARI 4mg/dMTX, ETN, ANA, ADALymphopenia under TOFAComplete Response: S, E, J M2 with BARI(83)M3J3 y12 mTOFA 1.6mg/dNSAID, MTX, GC, TOCI, ETNComplete Response: J M12(83)M9J7 y12 mTOFA 2.5mg/dNSAID, ETN, MTX, TOCIComplete Response: J M12(83)M2S, J2.5 y4 mTOFA 2.5mg/dNSAID, MTX, GC, TOCI, ETNComplete Response: S, J M4Abbreviations: ANA; anakinra; ADA, adalimumab; BARI, baricitinib; d, day; DOX, Doxycycline; E, eyes; ETN, etanercept; GC, glucocorticoids; J, joints; JAKi, Janus kinase inhibitor; L, lung; LN, lymph node; m, month; M, muscle; MTX, methotrexate; NSAID; non-steroidal anti-inflammatory drugs; Ref, reference; S, skin; TOCI, tocilizumab; TOFA, tofacitinib; w, week; y, year Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 4 Blau Syndrome Cases Treated with JAKi Published to Date Abbreviations: ANA; anakinra; ADA, adalimumab; BARI, baricitinib; d, day; DOX, Doxycycline; E, eyes; ETN, etanercept; GC, glucocorticoids; J, joints; JAKi, Janus kinase inhibitor; L, lung; LN, lymph node; m, month; M, muscle; MTX, methotrexate; NSAID; non-steroidal anti-inflammatory drugs; Ref, reference; S, skin; TOCI, tocilizumab; TOFA, tofacitinib; w, week; y, year Table S4.Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 6 Cutaneous Sarcoidosis Cases Treated With Topical JAKi Published to DateRefGenderAgeOrgan involvedDisease durationJAKi follow-upTreatmentPrevious treatmentOutcome(84)F50S, L5 y2.5 mTopical 2% TOFAx2/dTopical GC, Topical CNI, DOX, MTX,Partial response: S M2(85)M46S, LN, L9 y5 mTopical 2% TOFAx2/dTopical GC, Topical CNI, Topical ATRA, ADAP, HCQ, DOXPartial response: S M5(86)F26S, M Unknown6 mTopical 2% TOFAx2/dAZA, GCPartial response: S M6(86)F26S, M1 y6 mTopical 2% TOFAx2/dAZA, GOLPartial response: S M6(87)F44S, LN1 y6mTopical 2% TOFAx2/d and ADATopical GC, DOX, MTX, HCQ, ADAPartial response: S M6(88)F66S, CS, LUnknownUnknownTopical 1.5% RUXOx2/dTopical GC, MTX, INFComplete response: S M2Abbreviations: ADA, adalimumab; ADAP, adapalene; ATRA, tretinoin; AZA, azathioprine; CNI, calcineurin inhibitor; d, day; DOX, doxycycline; GC, glucocorticoids; GOL, golimumab; HCQ, hydroxychloroquine; JAKi, Janus kinase inhibitor; L, lung; LN, lymph node; m, month; M, muscle; MTX, methotrexate; Ref, reference; S, skin; TOFA, tofacitinib; RUXO, ruxolitinib; y, year. Characteristics, Previous Treatments, JAKi Treatment-Related Findings and Outcome of the 6 Cutaneous Sarcoidosis Cases Treated With Topical JAKi Published to Date Abbreviations: ADA, adalimumab; ADAP, adapalene; ATRA, tretinoin; AZA, azathioprine; CNI, calcineurin inhibitor; d, day; DOX, doxycycline; GC, glucocorticoids; GOL, golimumab; HCQ, hydroxychloroquine; JAKi, Janus kinase inhibitor; L, lung; LN, lymph node; m, month; M, muscle; MTX, methotrexate; Ref, reference; S, skin; TOFA, tofacitinib; RUXO, ruxolitinib; y, year. Introduction Sarcoidosis is an inflammatory granulomatous disease of unknown cause affecting the lungs in 90% of patients while extra-thoracic involvement is reported in 30-50% of cases(1). Sarcoidosis frequently results in disabling or life-threatening organ involvements requiring systemic treatment with oral corticosteroid being the current cornerstone treatment(2–4). However, this standard is increasingly being challenged by emerging corticosteroid-sparing strategies, particularly in thoracic forms(5). Nevertheless, corticosteroids remain the first-line therapy, especially in life-threatening or extra-thoracic manifestations. Even in such cases, they may be insufficient as monotherapy, and disease relapse is common during tapering(6,7). Several immunosuppressive agents have been evaluated in steroids refractory patients or as steroids-sparing treatments, mostly methotrexate, TNF-a inhibitors and cyclophosphamide with very low level of evidence supporting their use(3,8–12). Other targeted therapies such as rituximab, ustekinumab and golimumab have been evaluated in small prospective studies with disappointing results(13–15). JAK inhibitors (JAKi) are immunosuppressive agents used in myeloproliferative disorders, rheumatoid arthritis, psoriasis arthritis, and ulcerative colitis(16). JAK-STAT pathway represents a promising target for sarcoidosis treatment. STAT1 is upregulated in sarcoidosis, and that STAT1 activation has been shown to correlate with disease severity(17). STAT3 was also identified as a key regulator of organ fibrosis in sarcoidosis(18). Some recent reports suggested JAKi could induce disease response(19). However, these data remain scarce, and need to be expanded. We wish to report on four sarcoidosis patients treated with JAKi jointly with a systematic review of cases from literature. Patients and Methods Patient selection We retrospectively included all sarcoidosis patients treated with any JAK inhibitor between January 1st 2004 and May 30th 2023 at our center. As no formal registry exists for sarcoidosis or JAKi-treated patients, we performed a systematic search using keywords (“sarcoidosis” and the name of each JAKi molecule) in the electronic medical records. Only four patients were identified and included in the present analysis. Sarcoidosis was defined according to the ATS practice guideline: a clinic-radiological presentation consistent with sarcoidosis, histopathological support, and exclusion of other causes of granulomatous diseases or similar conditions(20). Literature search A literature search was conducted using PubMed, MEDLINE, EMBASE, and Cochrane Library, limited to the English language and to articles published between 2004 and 2024. Search was made with the key words “sarcoidosis” and “Janus kinase inhibitors” or any specific JAKi molecules (“tofacitinib”, “baricitinib”, “ruxolitinib”, “deucravacitinib”, “fedratinib”, “peficitinib”,”upadacitinib”, “ritlecitinib”, “momelotinib”, “pacritinib”, “filgotinib”, “decernotinib”,“abrocitinib”). Data collection Demographic and clinical characteristics, previous treatments, JAKi treatment and outcomes were collected from medical records (case reports) or in the published articles (systematic review). Due to study heterogeneity and missing data, denominators indicate the number of available data points. Follow-up was defined as the time from JAKi prescription to the last available medical visit. Efficacy and tolerance assessments The response to JAKi was classified as complete, partial, or refractory according to clinician reported outcome. Response was defined as; complete: absence of signs or symptoms (clinical, laboratory, radiological and/or physiological parameters with exclusion of sequelae-related findings) with successful steroids withdrawal and without immunosuppressant introduction; partial: improvement of signs or symptoms with steroids < 10 mg/d (prednisone equivalent); refractory: new or worsening signs or symptoms and/or steroids increase and/or new immunosuppressant drug. Patients with no outcome assessment were reported as lost to follow-up. Statistical analysis Results for categorical variables were expressed as number (%) while those for continuous variables, expressed as mean ± standard deviation or median [interquartile range (IQR)]. Analyses were computed with R software 4.0.2 version (R project for Statistical Computing). Ethical considerations The database is registered at the “Commission Nationale de l’Informatique et des Libertés” (decision 2238959v0). The investigation conforms with the principles outlined in the Declaration of Helsinki. In accordance with the ethical standards of our hospital’s institutional review board, the Committee for the Protection of Human Subjects, and French law, written informed consent was not needed for demographic, physiological and hospital-outcome data analyses because this observational study did not modify existing diagnostic or therapeutic strategies; however, patients were informed of their inclusion in the study. Results Case reports The characteristics of the cases we report are shown in Table 1. Table 1.Demographic and Pre/Post-JAKi Treatment Sarcoidosis Related-Findings of Our Four Additional Case ReportsCasesGenderAgeOrgan involvedDisease duration JAKi follow-upTreatmentPrevious treatmentsOutcome1M52CS, M, J, E, L16 y29 mTOFA 5mgx2/dMTX 10mg/wGC, MTX, HCQ, AZA, MMF, IFN, ADA, LEFPartial response: CS & M M3, GC maintained at 7.5 mg/dNormal 18-FDG-PET/CT at M82M43LN, S, J, B, E, P, CNS15 y32 mTOFA 5mgx2/dMTX 15mg/wGC, MTX, IFN, HCQ, DOX, TOCIComplete response: L, S & J M6 MTX 10 mg/w3F38LN, J1 y8 mUPA 15 mgx1/dMTX 20mg/wGC, MTX, TOCIComplete response: J M8, Stable LN4M56LN, L, CNS2.5 y9 mTOFA 5mgx2/dCERTO 400mgx2/mGC, MTX, IFN, CPPartial response: CNS M9, GC tapered at 5 mg/dAbbreviations: ADA, adalimumab; AZA, azathioprine; B, bones; CERTO, certolizumab; CNS, central nervous system; CP, cyclophosphamide; CS, cardiac sarcoidosis; d, day; DOX, doxycycline; E, eyes; GC, glucocorticoids; HCQ, hydroxychloroquine; IFN, infliximab; J, joints; JAKi, Janus kinase inhibitor; LEF, leflunomide; L, lung; LN, lymph node; m, month; M, muscle; MMF, mycophenolate mofetil; MTX, methotrexate; P, parotids; S, skin; TOCI, tocilizumab; TOFA, tofacitinib; UPA, upadacitinib; w, week; y, year Demographic and Pre/Post-JAKi Treatment Sarcoidosis Related-Findings of Our Four Additional Case Reports Abbreviations: ADA, adalimumab; AZA, azathioprine; B, bones; CERTO, certolizumab; CNS, central nervous system; CP, cyclophosphamide; CS, cardiac sarcoidosis; d, day; DOX, doxycycline; E, eyes; GC, glucocorticoids; HCQ, hydroxychloroquine; IFN, infliximab; J, joints; JAKi, Janus kinase inhibitor; LEF, leflunomide; L, lung; LN, lymph node; m, month; M, muscle; MMF, mycophenolate mofetil; MTX, methotrexate; P, parotids; S, skin; TOCI, tocilizumab; TOFA, tofacitinib; UPA, upadacitinib; w, week; y, year Patient #1: This 52-year-old man had a 16-year history of sarcoidosis with pulmonary, articular, and ocular involvement. Non-caseating granulomas were initially found on a salivary gland biopsy. Over the years, he received corticosteroids, hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, and leflunomide without sustained response. Infliximab was introduced due to persistent activity, then switched to adalimumab because of suspected TNF-inhibitor-induced lupus. Shortly after stopping adalimumab, he presented with cardiac involvement complicated by a resuscitated cardiac arrest. Given the severity of organ involvement, the limited therapeutic options, and prior intolerance to TNF inhibitors, tofacitinib 5 mg twice daily was initiated. He achieved complete clinical and radiological response within 6 months and remained relapse-free under tofacitinib, methotrexate, and low-dose prednisone after 29 months of follow up. Patient #2: A 43-year-old man with a 15-year history of ocular sarcoidosis initially presented with right eye panuveitis, which led to irreversible blindness despite corticosteroid therapy. Years later, he developed neurosarcoidosis with leptomeningeal involvement on brain MRI. High-dose corticosteroids were reintroduced but caused a serous retinal detachment in the left eye, raising serious concern about the risk of bilateral blindness. Steroids were therefore discontinued. Infliximab was initiated as a corticosteroid-sparing strategy but induced a severe anaphylactic reaction. Tocilizumab led to a partial response, but relapse occurred despite treatment intensification. Given the contraindications to corticosteroids and anti-TNF agents, and persistent neurologic and systemic disease, tofacitinib 5 mg twice daily was introduced in combination with methotrexate. The patient achieved complete and sustained response after 6 months, including resolution of neurological symptoms, maintained over 32 months of follow-up. Patient #3: This 38-year-old woman had an 18-year history of sarcoidosis initially misdiagnosed as seronegative rheumatoid arthritis. She was treated with corticosteroids, methotrexate, and adalimumab for over a decade with good control. At age 30, she developed hidradenitis suppurativa (HS), which was managed with antibiotics. Adalimumab was discontinued due to secondary skin infections, and etanercept was introduced. Later, she developed systemic symptoms with polyarthritis and fever; a diagnosis of Still’s disease was considered. After a new flare with systemic and articular symptoms, granulomatous involvement was confirmed on endobronchial biopsy. Tocilizumab was initiated but caused an urticarial rash with superinfections. Given the dual indication (sarcoidosis and HS) and the failure or intolerance to TNF and IL-6 inhibitors, upadacitinib 15 mg daily was started with methotrexate(21,22). The treatment led to sustained response of both articular and cutaneous symptoms after 8 months of treatment. Patient #4: A 56-year-old man was diagnosed with sarcoidosis three years earlier based on cervical lymph node and nasal biopsies, with associated thoracic involvement. Initially untreated due to the absence of major organ dysfunction, he later developed neurological symptoms with altered mental status and inflammatory CSF findings. High-dose corticosteroids failed to induce improvement. Infliximab was attempted but immediately provoked anaphylaxis. Cyclophosphamide was administered over six months with partial benefit, but relapse occurred soon after treatment completion. Certolizumab was then introduced but did not control neurological symptoms. In light of the refractory, relapsing neurosarcoidosis and contraindications to other immunosuppressants, tofacitinib 5 mg twice daily was initiated as a compassionate treatment. The patient progressively improved, with cognitive and functional recovery, while corticosteroid tapering was made until 5 mg/day. Literature review Fourty-five patients from 21 studies were included (Figure 1)(19,23–42) and evaluated jointly with our 4 patients. Systematic Review Of Literature Flow Chart. Literature review was made through Pubmed, Medline, Embase and Cochrane library, with the corresponding key words. A total of 49 articles were found. Selected articles concerned patients reports, retrospectives studies and prospective evaluations. Abbreviation: JAK, Janus kinase One case series involving 12 patients treated with tofacitinib was excluded due to insufficiently detailed case-level data(43). Patient’s characteristics are described in Table 2. Table 2.Characteristics, JAKi Treatment-Related Findings and Outcomes in the 49 Reported Sarcoidosis CasesVariablesn=49 Demographic characteristics Woman26/49 (53)Age, years55 [43-60] Sarcoidosis-related findings Time since diagnosis, years6 [1.5-17]Lung involvement37/49 (76)Stage I7/37Stage II13/37Stage III4/37Stage IV4/37Unknown9/37Skin31/49 (63)Extra-pulmonary lymph nodes17/49 (35)Joint12/49 (24)ENT8/49 (16)Eye8/49 (16)Kidney7/49 (14)Spleen or hepatic6/49 (12)Brain4/49 (8)Heart4/49 (8)Muscle2/49 (4) Glucocorticoids at JAKi initiation 23/49 (48)Median dose, mg/d15 [10-25]<5 mg/day4/23 (17)5-30 mg/day17/23 (74)>30 mg/day2/23 (9) Outcomes 1 Duration of follow-up, months8 [6-12]Time from JAKi introduction to clinical response, months3 [1.5-5.75]Complete response22/49 (45)Partial response24/49 (49)Evolving disease2/42 (4)Lost to follow up1/42 (2) Corticosteroid treatment modification None3/23 (13)Withdrawal11/23 (48)Tapering6/23 (26)Increase2/23 (9)Unknown1/23 (4)Abbreviations: CSAMI, Cutaneous Sarcoidosis Activity and Morphology Instrument; CT-SCAN, computed tomography; ENT, ear nose throat; GC, glucocorticoids; JAKi, Janus kinase inhibitor; PFT, pulmonary function test; SPECT-CT, Single photon emission computed tomography; 18-FGF-PET/CT, Fluorodeoxyglucose positron emission tomography. Continuous variables are expressed as median [interquartile range 25-75]; categorical variables are expressed as No. (%). 1The evaluation of skin involvement was based upon: CSAMI score n=18/31 (58%) or physician reported outcome 13/31 (42%). Lung or extra-pulmonary involvement upon: SPECT-CT or 18FDG-PET/CT n= 21/43 (49%), pulmonary function tests n=12/37 (32%), CT-scan 8/43 (19%) or chest X-ray alone 5/43 (12%). Characteristics, JAKi Treatment-Related Findings and Outcomes in the 49 Reported Sarcoidosis Cases Abbreviations: CSAMI, Cutaneous Sarcoidosis Activity and Morphology Instrument; CT-SCAN, computed tomography; ENT, ear nose throat; GC, glucocorticoids; JAKi, Janus kinase inhibitor; PFT, pulmonary function test; SPECT-CT, Single photon emission computed tomography; 18-FGF-PET/CT, Fluorodeoxyglucose positron emission tomography. Continuous variables are expressed as median [interquartile range 25-75]; categorical variables are expressed as No. (%). 1The evaluation of skin involvement was based upon: CSAMI score n=18/31 (58%) or physician reported outcome 13/31 (42%). Lung or extra-pulmonary involvement upon: SPECT-CT or 18FDG-PET/CT n= 21/43 (49%), pulmonary function tests n=12/37 (32%), CT-scan 8/43 (19%) or chest X-ray alone 5/43 (12%). Twenty-six women (53%) with a median age at treatment initiation of 55 [43-60] years and a median time from diagnosis to JAKi of 6 years [1.5-17]. All cases fulfilled ATS cases definition. Most frequent organ involvement were: lung 76%, skin 63%, extra-pulmonary lymph nodes 35%, joint involvement 24% and kidney 14%(34). The median dosage of steroids associated tO JAKi at treatment start was 15 [10-25] mg/day. Most treatments used before JAKi (Table S1) were: glucocorticoids 80 %, methotrexate 67%, hydroxychloroquine 36%, infliximab 27%, adalimumab 14%, mycophenolate 14%, azathioprine 14%. JAKi type and regimens are shown in Table 3. Table 3.Reason for JAKi Introduction and Adverse Events in the 49 Reported Sarcoidosis CasesVariablesn=49 Reason for JAKi introduction Not reported19/49 (39)As a corticosteroid sparing agent114/49 (29)Refractory disease211/49 (22)Non-sarcoidosis indication35/49 (10) JAKi treatment Tofacitinib41/49 (88)Ruxolitinib3/49 (7)Baricitinib2/49 (4)Upadacitinib2/49 (4)Abrocitinib1/49 (2) Adverse events None27/49 (55)Infection411/49 (22)Laboratory abnormalities53/49 (6)Metabolic64/49 (8)Abbreviations: JAKi, Janus kinase inhibitor. Categorical variables are expressed as No. (%).1Corticodependent diseases n=9, corticosteroids contraindication n=5. 2Frequent relapses n=6, compassionate treatment n=4, TNFα inhibitor-refractory disease n=1. 3Associated autoimmune disease requiring treatment escalation n=3 (rheumatoid arthritis n=1, inflammatory bowel disease n =1, hidradenitis suppurativa n=1), Associated myeloproliferative syndrome requiring treatment escalation n=2. 4Non-severe PCR-proven SARS-CoV2 infections n=5, bronchial infection n=4, acute sinusitis n=1 and urinary tract infection n=1. 5Transient lymphocytopenia n=2, transient elevated liver function test n=1 6Hyperlipidemia n=1, weight gain n=2, nausea n=1. Reason for JAKi Introduction and Adverse Events in the 49 Reported Sarcoidosis Cases Abbreviations: JAKi, Janus kinase inhibitor. Categorical variables are expressed as No. (%). 1Corticodependent diseases n=9, corticosteroids contraindication n=5. 2Frequent relapses n=6, compassionate treatment n=4, TNFα inhibitor-refractory disease n=1. 3Associated autoimmune disease requiring treatment escalation n=3 (rheumatoid arthritis n=1, inflammatory bowel disease n =1, hidradenitis suppurativa n=1), Associated myeloproliferative syndrome requiring treatment escalation n=2. 4Non-severe PCR-proven SARS-CoV2 infections n=5, bronchial infection n=4, acute sinusitis n=1 and urinary tract infection n=1. 5Transient lymphocytopenia n=2, transient elevated liver function test n=1 6Hyperlipidemia n=1, weight gain n=2, nausea n=1. Main reasons for JAKi introduction were: not reported 39%, as corticosteroid sparing agent 29%, refractory diseases 22% and non-sarcoidosis indication 10%. After a median follow-up time of 8 [6-12] months, the rates of complete, partial response and evolving disease were: 45%, 49% and 4% respectively (Table 2). The median time from JAKi introduction to clinical response was 3 [1.5-5.75] months. Steroids could be withdrawn or tapered in 48% and 26% of cases while there were maintained unchanged or increase in 13% and 9% respectively (Table 2). No serious adverse event were reported (Table 3), and most frequent were infections 22%, mainly mild respiratory symptomatic infection including Sars-COV2 infection. Pediatric cases from literature with NOD2 mutation-proven Blau syndrome treated with JAKi are described apart in Table S3. All had complete response under treatment. Cases treated with topical JAKi are described in Table S4. All had at least partial response under treatment. Discussion Sarcoidosis is a rare disease associated with substantial morbidity and mortality(44–46). Corticosteroid, its cornerstone treatment, is associated with substantial toxicity. There is an unmet need for effective second-line treatments, either as steroid-sparing agents or for refractory disease(7,47,8). We herein report early data suggesting JAKi might be effective in sarcoidosis with a good safety profile. Translational research data support the use of JAKi in sarcoidosis. STAT1 is upregulated in sarcoidosis(17). JAK-STAT pathway mediates several cytokines involved in the development and maintenance of granulomas, including interferon (IFN)-γ, IL-12, IL-18 and IL-10(48–50). Whole genome sequencing study reported the association of JAK2 variant and sarcoidosis(51). A large variety of cytokines have been implicated in the pathophysiology of sarcoidosis, and unlike single-target biologics, JAKi have a more pleiotropic anti-cytokine effect(8,15). Actual therapies used in sarcoidosis include Methotrexate, Azathioprine, Hydroxychloroquine and Anti-TNF agents. Methotrexate has shown efficacy as a steroid-sparing agent in prospective studies, and old series reported disease improvement among 66 % of the treated patients with multisystem sarcoidosis(52,53). Although methotrexate has traditionally been used as a second-line agent, the recent METHPRED study demonstrated its efficacy as a first-line monotherapy in pulmonary sarcoidosis(5). In contrast, patients treated with JAK inhibitors in our cohort had typically received multiple prior therapies—including methotrexate—and were refractory to conventional immunosuppressants(4). Azathioprine is reported as having the same efficacy, as a sparring agent, with good reported outcome in about 70% of cases(47). Hydroxychloroquine was mainly assessed in cutaneous and ocular sarcoidosis, with good reported outcome for about 50 % to 70% of cases(54,55). Finally, anti-TNF are the recommended treatment in refractory disease, and reported an efficacy around 70% in multisystemic disease, with a lower outcome in pulmonary disease(56,57). Two studies reported a response rate superior to 90 % for Infliximab in multisystemic disease(11,58). Notably, complete response was reported in fewer than 20% of cases in a multicenter French study(59). In this study, a favorable outcome with JAKi was reported in more than 90% of patients, with a complete response achieved in nearly one out of two individuals. JAKi are now approved in various immune-mediated diseases such as rheumatoid arthritis where JAKi are indicated as a second or third line therapy on top off methotrexate(60–65). They are also approved in spondylarthritis and psoriatic arthritis(66–69), and might be included in a near future in the therapeutic algorithm of alopecia Areata and inflammatory bowel diseases(70–72). Very few adverse events have been reported. Conversely to previous reports, and except for one pulmonary infection requiring hospitalization, no serious bacterial of viral infection occurred(36,73). Further, neither severe metabolic or thromboembolic events were reported while concerns have been raised in the literature(74–78). Given the retrospective nature of these studies and the short follow-up, these data should be interpreted with caution but real-life experience of JAKi in other diseases has shown a fair safety profile(79,80). This study has several limitations. First, before JAKi initiation, 20% patients did not receive steroids as first line treatment. This might be explained by a high prevalence of lone sarcoidosis skin diseases(81). Second, as the median follow up is short, the long-term safety and efficacy in JAKi need to be evaluated. There was no relapse after 38 months of treatment in the case report with the longest follow up duration(32,35). Third, these data emerge from many proteiform retrospective studies, numerous case reports, and only two prospective studies, making the risk of publication bias substantial(19,33). Finally, we were unable to properly extract and analyze the data from one retrospective case series, but the results from the retrospective case series involving 12 patients treated with Tofacitinib are consistent with our findings, with 6 responders and 3 declared non responders to treatment(43). These results will need to be challenged in further prospective studies, as the current evidence is predominantly based on retrospective series and isolated case reports, which are inherently prone to publication bias—especially since non-responding cases are less likely to be published. This risk of bias is especially high, considering that numerous studies reported here include fewer than five cases. However, in the context of rare and heterogeneous diseases such as sarcoidosis—particularly in its extrapulmonary, refractory, or corticosteroid-intolerant forms—case reports often represent the only available published data. While we chose to include all published cases regardless of series size to provide a comprehensive overview, we fully acknowledge that the most reliable assessment of therapeutic efficacy should come from randomized controlled trials, followed by prospective series, then retrospective cohorts, and finally individual case reports. This hierarchy should be kept in mind when interpreting our findings. Fourth, while JAKi seems to be effective in controlling sarcoidosis and allowing steroids taper, it is unclear if it has a transient or a long-lasting effect after JAKi tapering or interruption. Fifth, data are lacking on long-term pulmonary function evolution under JAKi. Conclusion JAKi treatment seems to be a promising therapeutical class in sarcoidosis patients dependent or refractory to corticosteroids and conventional immunosuppressant. As many questions remain unanswered, further prospective studies now are needed to evaluate the efficacy of JAKi in sarcoidosis.